Physician profile
Graham Holt
NPI 1033112446
$2,069.96
in general payments reported to CMS, 2019-2025
12 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $111 · 2021: $102 · 2022: $89.82 · 2023: $405 · 2024: $507 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $976.19 | 2019-2025 | Clareon, Hydrus Microstent, Argos |
| Rxsight INC | $342.95 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $229.31 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $147.07 | 2019-2020 | |
| Carl Zeiss Meditec USA, INC. | $114.72 | 2024 | Cirrus Hd-Oct |
| Abbvie INC. | $102.17 | 2022-2025 | |
| Eyevance Pharmaceuticals LLC | $41.54 | 2022 | |
| Coopervision INC. | $40.09 | 2023-2024 | Myday Contact Lens |
| Abb Con-Cise Optical Group LLC | $21.42 | 2024 | Contact Lens, Spectacle Lenses |
| Sight Sciences, INC. | $20.33 | 2023 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $20.12 | 2023 | |
| Aerie Pharmaceuticals, INC. | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Graham Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.